---
title: "Morgan Stanley nearly doubled its price target for CRISPR Therapeutics. Is the gene-editing stock a no-brainer buy?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294425425.md"
description: "The next six months may be decisive for the biotech."
datetime: "2026-07-30T23:00:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294425425.md)
  - [en](https://longbridge.com/en/news/294425425.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294425425.md)
generator: "portal-rs"
---

# Morgan Stanley nearly doubled its price target for CRISPR Therapeutics. Is the gene-editing stock a no-brainer buy?

The next six months may be decisive for the biotech.

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP](https://longbridge.com/en/news/295199690.md)
- [Kivo and CRISPR Therapeutics to Present 52-Day QMS Modernization at DIA 2026 in Philadelphia](https://longbridge.com/en/news/289194590.md)
- [bit.bio launches ioScreen CRISPR screening service for human iPSC-derived cell models](https://longbridge.com/en/news/295776409.md)
- [Legend Biotech Sets September 24, 2026 AGM With Expanded Equity Plan on Agenda](https://longbridge.com/en/news/296267145.md)
- [Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline](https://longbridge.com/en/news/296187977.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**